Amevive
Term · Oncology and biomedicine · MLC-T-ONC-000442
A drug that is used to treat certain skin conditions and is being studied in the treatment of cutaneous (skin-related) T-cell cancer and T-cell non-Hodgkin lymphoma. Amevive is made by combining part of an antibody with a protein that blocks the growth some types of T cells. It is a type of fusion protein and a type of immunosuppressant. Also called alefacept.
| Identifier | MLC-T-ONC-000442 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | alefacept |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-000442",
"term": "Amevive",
"field": "Oncology and biomedicine",
"definition": "A drug that is used to treat certain skin conditions and is being studied in the treatment of cutaneous (skin-related) T-cell cancer and T-cell non-Hodgkin lymphoma. Amevive is made by combining part of an antibody with a protein that blocks the growth some types of T cells. It is a type of fusion protein and a type of immunosuppressant. Also called alefacept.",
"synonyms": [
"alefacept"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/amevive/"
}
Record 952 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.